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Abstract: Recent research revealed that autism spectrum disorders (ASD) and cancer may share
common genetic architecture, with evidence first reported with the PTEN gene. There are
approximately 800 autism genes and 3500 genes associated with cancer. The VarElect phenotype
program was chosen to identify genes jointly associated with both conditions based on genomic
information stored in GeneCards. In total, 138 overlapping genes were then profiled with
GeneAnalytics, an analysis pathway enrichment tool utilizing existing gene datasets to identify
shared pathways, mechanisms, and phenotypes. Profiling the shared gene data identified seven
significantly associated diseases of 2310 matched disease entities with factors implicated in shared
pathology of ASD and cancer. These included 371 super-pathways of 455 matched entities reflecting
major cell-signaling pathways and metabolic disturbances (e.g., CREB, AKT, GPCR); 153 gene
ontology (GO) biological processes of 226 matched processes; 41 GO molecular functions of 78
matched functions; and 145 phenotypes of 232 matched phenotypes. The entries were scored and
ranked using a matching algorithm that takes into consideration genomic expression, sequencing, and
microarray datasets with cell or tissue specificity. Shared mechanisms may lead to the identification
of a common pathology and a better understanding of causation with potential treatment options to
lessen the severity of ASD-related symptoms in those affected.
Keywords: autism spectrum disorders (ASD); cancer; overlapping genes and gene profiling;
super-pathways; phenotypes and diseases; molecular functions and processes
1. Introduction
Autism spectrum disorders (ASD) include an array of conditions arising from
neurodevelopmental defects during a crucial stage of brain formation characterized by deficits
in communication ability, a paucity of social skills, repetitive behaviors, and narrow interests [1].
Environmental factors and perinatal care may play a role in both ASD onset and severity, but often
arises from a substantial genetic burden. Colvert et al. [2] found heritability estimates of 56% to 95%
among monozygotic twins, with additive genetic factors comprising a significant share of the burden.
Morphologically, the brains of individuals diagnosed with ASD contain abnormal neuronal
growth patterns, including an overabundance of neurons and unusual dendritic spine profiles [3,4].
Butler and others in 2005 [5] suggested that common causal factors could contribute to both abnormal
neuronal development, autism, and risk for malignancy in patients with autism, with macrocephaly
and PTEN gene mutations seen in about one-fifth of affected individuals. PTEN is an important
tumor-suppressor gene reported to play a role in tumor growth, hamartoma disorders (e.g., Cowden,
Proteus, Bannayan–Riley–Ruvalcaba syndrome), overgrowth, and cancer [6–8]. Several of these
overgrowth-related disorders are also at risk of developing malignancy, particularly colorectal cancer.
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The genetic architecture of ASD was extensively surveyed through genome-wide association
studies (GWAS) and candidate gene approaches [9–11]. Several pathways and mechanisms were
proposed as mediating factors in the pathogenesis of disorders, although the causative agents of
the vast majority of cases remain elusive. However, cross-talk between the canonical Wnt pathway,
the Notch signaling cascade [12], and other disturbed genes and pathways [13,14] are believed to
play a potential role and helpful in explaining an association with malignancy [15,16]. Furthermore,
MAPK and calcium signaling pathways, particularly overlapping calcium-PKC–Ras–Raf–MAPK/ERK
processes are strongly associated with ASD. These pathways play a central role in a large range
of biological processes and, when abnormal, may compromise biological output and contribute to
neuropsychiatric disorders, cell growth, and malignancy [17–20].
The PTEN gene product behaves as an inhibitor of the phosphoinositol 3-kinase/AKT
pathway [21]. Disturbances contribute to dysregulation in the pathway leading to excessive
uncontrolled cell growth and malignancy. Butler et al. [5] and Varga et al. [21] previously reported
elevated frequencies of heterozygous germline PTEN gene mutations in the ASD population,
suggesting that mutations serve as a critical component of the shared cancer and ASD etiology
requiring further research. Investigation into the connection of other genetic factors contributing to
ASD and cancer could be of clinical utility. Individuals diagnosed with autism should be screened
more frequently for cancers for which they may have a genetic susceptibility.
In the investigation herein, we utilized GeneAnalytics, which incorporates a computer-based
bioinformatics pipeline developed by GeneCards, to identify and interrogate shared genes and their
architecture between cancer and ASD. We explored influential shared pathways in overlapping genes
which could represent potential therapeutic targets. We reviewed reports on the overlap between
approximately 800 autism and over 3500 cancer-related genes utilizing this bioinformatics/pathway
analysis program. GeneCards was used as an integrated, human genomic database to leverage
information from 125 scholarly databases including genetic, transcriptomic, proteomic, functional,
and clinical information to interrogate genomic-related data for our study [22,23]. This novel study
may supply information helpful to stimulate or address a potential medical or genetic conundrum and
may provide a research-based foundation of common pathology in ASD and cancer.
2. Results
Using the VarElect program, autism and cancer genes were screened for overlapping units,
according to phenotype category. VarElect identified 138 genes in common between the 792 reported
known, susceptible, or clinically relevant genes for autism or ASD (17.4%), and 3.9% of approximately
3500 genes implicated in cancer. The 138 genes and their underlying biological functions were profiled
by the commercially available GeneAnalytics program, previously validated in studies of random
genes to test the interpretation power or relationship to the gene set under investigation [22].
The GeneAnalytics output furnished a list of diseases highly associated with the combined cancer
and autism gene set. The resulting high score matches (p < 0.05) are presented, ranked by score,
and categorized by disease type in Table 1. The number of matched genes between the indicated
disease and the autism and cancer gene set is included for context. Seven diseases were found to be
significantly associated with the dataset, all of which pertain to cancer (see Figure 1). Three of the
cancers are reproductive in nature (breast, prostate, and endometrial), while two are gastrointestinal
(colorectal and pancreatic).
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Table 1. Profiling of high scores in overlapping genes for autism and cancer-associated diseases.
Score Disease Disease Categories Number of Matched
Genes (% of 138
Overlapping Genes)
33.84 Colorectal cancer Gastrointestinal diseases, genetic diseases, rare
diseases, cancer diseases
44 (32%)
30.70 Breast cancer Reproductive diseases, genetic diseases, rare
diseases, cancer diseases
39 (28%)
24.13 Prostate cancer Reproductive diseases, genetic diseases, rare
diseases, cancer diseases
31 (22%)
19.01 Lung cancer Respiratory diseases, genetic diseases, cancer
diseases
25 (18%)
18.43 Endometrial cancer Reproductive diseases, genetic diseases, rare
diseases, cancer diseases
19 (14%)
13.94 Leukemia, acute
myeloid
Immune diseases, blood diseases, genetic
diseases, rare diseases, cancer diseases
15 (11%)
13.64 Pancreatic cancer Gastrointestinal diseases, endocrine diseases,
genetic diseases, rare diseases, cancer diseases
15 (11%)
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Figure 1. Diseases ranked by score and match rate (size of circle). 
Super-pathways were likewise ranked and scored based on degree of association with the gene 
set. Top-scoring super-pathways are presented with matching rates in Table 2, restricted to the top 
30 of 371 significant entries (p < 0.05). These included ubiquitous signaling super-pathways such as 
GPCR (score = 166, 54% match with gene set) and ERK (score = 146, 38% match). Numerous additional 
signaling super-pathways were found to be significantly associated with the combined gene set, 
including AKT, HGF development, CREB, cAMP-dependent PKA, fMLP, P70S6K, RET, TGF-β, PEDF 
induced, MTOR, and PI3K/AKT. Cancer-specific super-pathways, including “glioma” and 
“pathways in cancer”, were also implicated at a statistically significant level (p < 0.05) (see Figure 2). 
 
Figure 1. Diseases ranked by score and match rate (size of circle).
Super-pathways were likewise ranked and scored based on degree of association with the gene
set. Top-scoring super-pathways are presented with matching rates in Table 2, restricted to the top
30 of 371 significant entries (p < 0.05). These included ubiquitous signaling super-pathways such
as GPCR (score = 166, 54% match with gene set) and ERK (score = 146, 38% match). Numerous
additional signaling super-pathways were found to be significantly associated with the combined gene
set, including AKT, HGF development, CREB, cAMP-dependent PKA, fMLP, P70S6K, RET, TGF-β,
PEDF induced, MTOR, and PI3K/AKT. Cancer-specific super-pathways, including “glioma” and
“pathways in cancer”, were also implicated at a statistically significant level (p < 0.05) (see Figure 2).
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Table 2. Profiling of high scores in overlapping genes for autism and cancer-associated super-pathways.
Score Super-Pathways Number of
Total Genes
Number of
Super-Pathway
Matched Genes
% of 138
Overlapping
Genes
166.10 Elk-related tyrosine kinase (ERK) signaling 1177 74 54%
145.73 glioma 313 44 32%
131.74 G-protein coupled receptor (GPCR) pathway 708 53 38%
122.48 Pathways in cancer 395 42 30%
116.32 Signaling by GPCR 2601 80 58%
113.29 Phospholipase-C pathway 498 43 31%
98.91 Human immune-deficiency virus (HIV) life cycle 865 48 35%
97.32 NANOG in mammalian embryonic stem cell
pluripotency
533 40 29%
95.18 Apoptotic pathways in synovial fibroblasts 725 44 32%
95.13 AKT murine thymoma viral oncogene homolog (AKT)
signaling
681 43 31%
94.06 Development HGF signaling 234 30 22%
90.05 CAMP response element-binding protein (CREB)
pathway
528 38 28%
81.54 Integrated breast cancer pathway 154 24 17%
81.30 Proteoglycans in cancer 203 26 19%
80.40 Nuclear factor of activated (NFAT)
T cells and cardiac hypertrophy
326 30 22%
78.97 Integrin pathway 568 36 26%
78.26 Development of vascular endothelial growth factor
(VEGF) signaling via VEGFR2, generic cascades
147 23 17%
77.70 Activation of cyclic adenosine monophosphate
(CAMP)-dependent protein kinase A (PKA)
628 37 27%
77.43 Formyl peptide receptor (FMLP) pathway 317 29 21%
77.00 P70S6K signaling 390 31 22%
74.95 Rearranged during transfection (RET) signaling 974 43 31%
72.42 Transforming growth factor (TGF)-beta pathway 652 36 26%
72.03 Glioblastoma multiforme 111 20 14%
71.00 Pigment epithelium-deprived factor (PEDF) induced
signaling
721 37 27%
70.30 P21-activated kinase (PAK) pathway 682 36 26%
69.39 Endometrial cancer 122 20 14%
67.08 Mechanistic target of rapamycin (MTOR) signaling
pathway (KEGG)
209 23 17%
66.63 PI3K/AKT signaling pathway 342 27 20%
66.33 Developmental biology 1079 42 30%
65.44 Focal adhesion 283 25 18%Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 15 
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Statistically significant Gene Ontology (GO) biological processes are presented in Table 3, which
are limited to the top 30 of 153 total high-scoring matches. The top three entries directly relate to the
regulation of gene expression. These include “positive regulation of transcription, DNA-templated”,
“positive regulation of transcription from RNA polymerase II promoter”, and “positive regulation
of gene expression”, which exhibited matching rates of 21%, 25%, and 15%, respectively, with the
combined 138 overlapping gene set (see Figure 3).
Table 3. Profiling of high scores in overlapping genes for autism and cancer-associated Gene Ontology
(GO) biological processes.
Score GO Biological Processes Number of
Total Genes
Number of
Matched Genes
% of 138
Overlapping Genes
53.00 Positive regulation of transcription, DNA-templated 596 29 21%
46.66 Positive regulation of transcription from RNA
polymerase II promoter
1016 34 25%
44.49 Positive regulation of gene expression 346 21 15%
44.10 Heart development 232 18 13%
42.44 Negative regulation of cell proliferation 419 22 16%
41.44 Nervous system development 535 24 17%
39.38 Intracellular signal transduction 467 22 16%
39.37 Protein phosphorylation 629 25 18%
39.02 Positive regulation of apoptotic process 330 19 14%
37.45 Positive regulation of protein phosphorylation 155 14 10%
36.52 Apoptotic process 690 25 18%
36.16 Positive regulation of sequence-specific DNA-binding
transcription factor activity
105 12 9%
34.58 Positive regulation of cell proliferation 500 21 15%
34.22 Negative regulation of apoptotic process 507 21 15%
33.45 Phosphorylation 700 24 17%
31.65 Canonical Wnt signaling pathway 80 10 7%
31.62 Cell adhesion 620 22 16%
31.02 Phosphatidylinositol-mediated signaling 112 11 8%
30.96 Signal transduction 2032 40 29%
29.94 Response to drug 323 16 12%
29.83 Thymus development 44 8 6%
29.33 Visual learning 46 8 6%
28.92 Extracellular matrix organization 203 13 9%
28.09 Protein autophosphorylation 173 12 9%
27.55 Negative regulation of transcription from RNA
polymerase II promoter
724 22 16%
27.40 Cell-cycle arrest 143 11 8%
27.05 Regulation of phosphatidylinositol 3-kinase signaling 82 9 7%
26.20 Substrate adhesion-dependent cell spreading 39 7 5%
25.00 Negative regulation of cysteine-type endopeptidase
activity involved in apoptotic process
68 8 6%
24.79 Peptidyl-tyrosine phosphorylation 171 11 8%
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Table 4. Profiling of high scores in overlapping genes for autism and cancer-associated GO
molecular functions.
Score GO Molecular Functions Number of
Total Genes
Number of
Matched Genes
% of 138
Overlapping Genes
66.97 Protein binding 9013 115 83%
43.40 Enzyme binding 360 21 15%
36.09 β-Catenin binding 80 11 8%
35.87 Protein kinase activity 530 22 16%
30.98 Kinase activity 698 23 17%
30.91 Transcription factor binding 308 16 12%
27.55 Transmembrane receptor protein tyrosine kinase activity 54 8 6%
27.38 Identical protein binding 797 23 17%
25.54 Protein kinase binding 402 16 12%
25.40 Protein tyrosine kinase activity 164 11 8%
23.70 Transcription regulatory region DNA binding 229 12 9%
21.10 Phosphatidylinositol-4,5-bisphosphate 3-kinase activity 66 7 5%
20.68 Protein phosphatase binding 69 7 5%
20.58 RNA polymerase II Core promoter proximal region
sequence-specific DNA binding
336 13 9%
20.43 Protein C-terminus binding 185 10 7%
19.66 Ubiquitin protein ligase binding 299 12 9%
18.88 Transcriptional activator activity, RNA polymerase II
core promoter proximal region sequence-specific
binding
260 11 8%
17.81 Repressing transcription factor binding 34 5 4%
17.69 Protein homodimerization activity 758 18 13%
17.69 Chromatin binding 404 13 9%
17.45 Cell adhesion molecule binding 63 6 4%
17.27 C–X3–C chemokine binding 5 3 2%
16.82 Protein heterodimerization activity 495 14 10%
16.48 Nitric-oxide synthase regulator activity 6 3 2%
16.19 Androgen receptor binding 43 5 4%
15.95 Protein domain specific binding 264 10 7%
15.57 Transferase activity 1759 28 20%
15.54 Receptor binding 398 12 9%
15.50 Nuclear hormone receptor binding 23 4 3%
15.28 Transcription factor activity, sequence-specific DNA
binding
1029 20 14%
The 30 top scoring phenotypes, of 145 significant matches, are outlined in Table 5. Phenotypes
reflect the importance of ASD and cancer-associated genes in growth and development-related
processes (see Figure 5). The top phenotypes include “premature death” (score = 70, 28% match rate),
“complete embryonic lethality during organogenesis” (score = 53, 20% match rate), and “decreased
body size” (score = 51, 22% match rate).
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Table 5. Profiling of high scores in overlapping genes for autism and cancer-associated phenotypes.
Score Phenotypes Number of
Total Genes
Number of
Matched Genes
% of 138
Overlapping Genes
70.49 Premature death 832 39 28%
53.00 Complete embryonic lethality during organogenesis 540 28 20%
51.00 Decreased body size 742 31 22%
46.85 Decreased body weight 1144 36 26%
37.37 Decreased embryo size 450 21 15%
36.64 Decreased thymocyte number 102 12 9%
34.08 Embryonic growth retardation 404 19 14%
33.98 Increased leukocyte cell number 120 12 9%
33.98 Enlarged heart 120 12 9%
33.25 Abnormal heart development 158 13 9%
33.05 Decreased B-cell number 196 14 10%
29.78 Partial embryonic lethality during organogenesis 234 14 10%
29.60 Partial postnatal lethality 546 20 14%
29.50 Increased tumor incidence 124 11 8%
28.15 Enlarged spleen 256 14 10%
27.97 Abnormal sensory neuron innervation pattern 52 8 6%
27.76 Abnormal rostral–caudal axis patterning 53 8 6%
27.60 Complete prenatal lethality 264 14 10%
27.18 Partial perinatal lethality 225 13 9%
27.13 Hyperactivity 271 14 10%
27.09 Abnormal blood vessel morphology 146 11 8%
27.04 Increased mammary adenocarcinoma incidence 20 6 4%
26.94 Complete lethality throughout fetal growth and
development
186 12 9%
26.90 Abnormal response/metabolism to endogenous
compounds
83 9 7%
26.76 Complete postnatal lethality 378 16 12%
25.78 Abnormal B-cell differentiation 91 9 7%
25.38 Abnormal definitive hematopoiesis 94 9 7%
24.21 Abnormal heart morphology 178 11 8%
24.05 Decreased sensory neuron number 14 5 4%
23.89 Partial prenatal lethality 274 13 9%
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3. Discussion
As anticipated in our examination of gene data and profiling, the diseases found most in common
with the combined autism and malignancy gene set did pertain to cancer. Moreover, colorectal
cancer accounted for 32% of overlapping genes, followed by breast and prostate cancer (see Table 1).
Two notable exceptions of our own cut-off criteria that may deserve further inspection include
Alzheimer disease and amyotrophic lateral sclerosis (ALS), both of which approached but did not
attain significance in their association with the gene set, achieving medium scores. Alzheimer disease
and ALS are progressive neurodegenerative diseases [23–25]. Alzheimer disease and ALS exhibited
11% and 8% overlap with the ASD and cancer gene set, which is a small, though not trivial connection.
Enrichment of genes associated with neurodegenerative illnesses among the autism and cancer gene
set may be indicative of shared disturbances in neurological growth and development which could
contribute to the divergent morphology of autism, cancer, Alzheimer disease, and ALS.
Regarding diseases cited in Table 1, one unusual observation was the lack of representation
of brain and neurological diseases. Of the seven high-score matches and six selected borderline
(medium-score) matches, only medulloblastoma qualified as a cancer of the brain and nervous system.
Reproductive cancers (breast, prostate, and endometrial) and gastrointestinal cancers (colorectal,
pancreatic, and hepatocellular carcinoma) were more prevalent. Notably, most of the cancers listed in
Table 1 tend to be acquired diseases with a genetic diathesis (e.g., breast and prostate), as opposed to
congenital diseases that arise early in development (medulloblastoma). It should also be noted that
tumors of the ectoderm and endoderm were disproportionately represented relative to the mesoderm.
This may reflect the tissue-specific nature of neural development in the onset of autism. Of note,
ASD did not achieve statistical significance with the shared dataset, despite being a requisite for
selection and receiving a relatively high-scoring entry. This may be a testament to the complexity of
autism spectrum disorder. Even though the gene set was filtered by ASD connection, collectively, the
combined genes were more diagnostic of cancer than ASD.
Overall, the highest-scoring super-pathways correlated more strongly with the autism and cancer
combined gene set (as evidenced by the higher scores), compared to GO biological processes and
GO molecular functions, which were not as strongly correlated, as reflected by their lower scores.
The majority of super-pathways (see Table 2) in the top 30 reported entries in the high-scoring
category achieved a match rate of at least 20% with the gene set, indicating the relative importance
of these super-pathways in the autism and cancer connection. The GeneAnalytics output of the
highest scores strongly implicated the ERK signaling pathway in shared pathogenesis based on
super-pathway analysis, with a score of 166 and a match rate of 54%, followed by the GPCR pathway
at 38%. The MAPK/ERK signaling pathway occupies a key role in mitogen signaling and cell
growth with survival [26]. Disturbances in the ERK pathway can disrupt the cell cycle, leading
to anomalous cell proliferation and malignant growth. Gene mutations or aberrant functioning in the
pathway during early development could contribute to abnormal neuronal growth in ASD. Alterations
in GPCR signaling could further contribute to the onset of ASD through aberrant cell signaling
and neurotransmitter dysregulation, both of which might lead to changes in cognitive functioning
characteristic of ASD.
For GO biological processes, the three highest-scoring entries pertain to the regulation of gene
expression. The outcome of the analysis suggests that an important mechanism in the mutual pathology
of autism and cancer may be attributed to variation in transcription factors and nongenic sequences
and, hence, differences in the regulation and rate of gene expression. Processes involved in the
growth, development, and death of cells were found to be highly associated with the gene set. Indeed,
“positive regulation of apoptotic process”, “apoptotic process”, and “negative regulation of apoptotic
process” were each flagged as biological processes significantly associated with the combined gene
set, with scores of 39 (matching rate of 14%), 37 (18%), and 34 (15%), respectively. Additional growth
and death biological processes were also found to be enriched in the gene set, including “heart
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development”, “negative regulation of cell proliferation”, “nervous system development”, “positive
regulation of cell proliferation”, and the “canonical Wnt signaling pathway”.
In terms of the GO molecular functions underlying cancer and autism pathology, the results
strongly implicate “protein binding”, which exhibited a score of 67, over 20 points larger than the
second, less inclusive entry, “enzyme binding”. Furthermore, 83% of the autism and cancer gene set
with 115 out of 138 matched genes was associated with protein binding, suggesting that dysfunction in
protein binding may play a significant role in the shared autism and cancer diathesis. In many respects,
this paradigm is reflective of the pivotal role of protein binding in the diverse metabolic processes
underlying growth and survival. There was a substantial disparity between the high matching rate of
protein binding (83%) and that of enzyme binding specifically (15%). The remaining 68% of protein
binding that is not explained by enzyme binding and activation by kinase pathways may be attributed
to structural protein and signal–receptor binding. This may suggest that structural and signaling
mechanisms are disproportionately involved in the shared pathology of cancer and autism as noted
previously. MAPK and calcium signaling pathways in genes associated with autism are found in other
disorders including cancer [19]. Enzymes may play more of a peripheral role. Enzyme binding overlaps
with kinase pathways, many of which are involved in enzyme activation. Kinase and phosphatase
activities were also prevalent among the high-scoring entries. Ten of the 30 highest-scoring molecular
functions pertain to kinase or phosphatase activity. Both protein binding and kinase activities align
with “protein kinase binding”.
The report also implicated β-catenin binding (score of 36; 8% matching rate); β-catenin functions as
both a moderator of gene transcription and as an agent of intercellular adhesion [27]. Overexpression
of β-catenin, which is encoded by the CTNNB1 gene, is well characterized as a candidate in the
pathogenesis of numerous cancers, as well as heart disease (this may serve as a potential link to
the high-scoring GO biological process of “heart development”) (score = 44; match rate = 13%) [28].
The relationship between β-catenin signaling and autism was reported, as β-catenin is dependent on
the absence of Wnt [29,30]. Its role in mediating cell adhesion and cellular development suggests it
may be a candidate in the pathogenesis of both autism and cancer.
The two highest-scoring phenotypes, “premature death” and “complete embryonic lethality
during organogenesis”, reflect the delicacy of neurogenesis and embryonic development. It is likely
that only certain combinations of mutations inherited from the autism and cancer gene set can be
tolerated and that, at a certain genetic burden, dysfunction in pathways associated with these genes
results in irretrievable failure to develop. Designated decreased body size and body weight may also
reflect the vital importance of these genes in mediating development, early cell division and number,
and the potential consequences of dysfunction.
Three functional pathways are potentially involved, which include genes and pathways for
chromatin remodeling, (e.g., CHD7, MECP2, DNMT3A, and PHF2), Wnt (e.g., CHD8, PAX5, and
ATRX), and other signaling super-pathways (e.g., GPCR, ERK, RET, and AKT) and mitochondrial
dysfunction in ASD (e.g., Reference [30]). Theoretically, drugs could be targeted to treat ASD.
By developing a rank-ordered list of functional categories significantly associated with autism and
cancer using GeneAnalytics pathways and profiling of shared autism and cancer genes, we identified
potentially high-impact pathways and common mechanisms which may serve as therapeutic targets
in future studies.
The interconnected relationship between autism and cancer invites further investigation in the
pathogenesis of the two seemingly unrelated disorders, and it warrants a pharmacological basis of
treatment. PTEN is an example of a shared gene for autism and cancer and the direct and indirect
subject of several formally approved cancer therapeutics including cisplatin, erlotinib, everolimus,
cetuximab, and estradiol. For example, cisplatin circumscribes DNA synthesis, activates caspase-3,
and facilitates apoptosis, thus rescuing the function of mutant PTEN [31]. Considering the role of
cisplatin in complementing PTEN function, strategic application of the drug could potentially address
the autism-associated symptoms arising from PTEN dysfunction. Another drug example is everolimus,
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which behaves as an inhibitor of the mammalian target of rapamycin, and it could impact cancer
predisposition and possibly autism development in a manner similar to cisplatin [32].
Although invasive drugs and treatments exist for many types of cancer, a drug is yet to be
successfully developed to prevent the onset or progression of ASD symptomology. The unexpected
shared etiology with overlapping genes between cancer and autism, particularly those involved in
cell-signaling pathways such as MAPK and calcium signaling [19], encourages cautious speculation
that, as our knowledge of the staging and mechanisms of ASD improves and applied to animal model
testing, the leverage of anti-cancer drugs at minimal dosages could be postulated. For example,
the 16p11.2 chromosome deletion is one of the most common copy number variants linked to
autism in humans and reportedly involves the ERK1 gene and other related genes converging in
the ERK/MAP kinase pathway. This pathway was the most recognized super-pathway found in
our profiling analysis of autism and cancer genes (see Table 2). Perturbations of this pathway can
contribute to neuropsychiatric disorders, cell growth, and malignancy; therefore, treatment could
lessen these manifestations. To investigate whether pharmacological approaches could be helpful,
researchers used a 16p11.2 equivalent deletion mouse model with the ERK1 gene deleted, and they
found that pharmacological inhibitions of ERK signaling (i.e., RB1 and RB3 peptides) rescued cortical
cytoarchitecture abnormalities and the abnormal behavioral phenotype associated with this deletion,
providing evidence for a potential targeted therapeutic intervention for autism [33]. Hypothetically,
treatment could lessen the effects of autism when recognized early and during brain plasticity.
Furthermore, genetic analysis linked autism with mutations in tumor suppression genes and other
cancer-associated genes and pathways reflected in our gene profiling analysis. Important candidate
genes (e.g., PTEN, NF1, and BRCA2) are found meeting criteria clearly associated with predisposition
to cancer such as colorectal, other gastrointestinal tumors, and breast reported in the top seven autism
and cancer-associated diseases (see Table 1). For example, mutations in the PTEN gene are linked to
colorectal, thyroid, head, neck, prostate, skin, breast, and lung cancer and about 10% of children with
autism have PTEN gene mutations, making this an important gene to target regarding therapeutic
intervention for autism with predisposition to cancer. ASDs and cancer overlap extensively in signal
transduction pathways as illustrated by our study, involving metabolic processes; these areas should
be targeted by treatment strategies. Such insights may enable more accurate gene-informed cancer risk
assessment for targeted therapeutic and medical management.
To date, there were a few preclinical models tested with anticancer medication on ASD symptoms.
For example, Kilincaslan et al. [34] reported the beneficial effects of everolimus on autism and
attention-deficit hyperactivity disorder (ADHD) symptoms in a group of patients with tuberous
sclerosis complex (TSC). This drug inhibits mTOR, one of the top 30 super-pathways identified with
high scores when comparing shared autism and cancer genes. It is a treatment for TSC in which autism
is a finding, along with renal angiomyolipomas and astrocytomas. The drug reduced tumor growth,
decreased seizures, and improved autistic, ADHD, and depression symptoms. However, there is a
paucity of studies on the effects of this drug on neuro-psychiatric symptoms, which merit further
consideration. Treatment would be a new avenue to pursue and further explore, particularly in those
with ASD, the involvement of shared autism and cancer-related genes.
4. Materials and Methods
Shared genetic architecture between cancer and ASD was examined firstly using VarElect,
a sequence phenotyper affiliated with GeneAnalytics (Alameda, CA, USA) [35,36]. A reported list
of 792 clinically relevant, susceptible, or known genes for ASD, summarized previously by Butler
et al. [37], and over 3500 recognized cancer genes found in the GeneAnalytics databases were entered
into the VarElect phenotyper program to identify overlapping genes.
The ASD genes were filtered by their association with the query “cancer” and limited to those
with established pathways. Based on the above parameters, VarElect produced 138 genes with known
connections to both cancer and ASD. The refined list of 138 genes was then entered into GeneAnalytics,
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a gene set analytical tool which uses GeneCards, an integrated genomic database, to parse genes and
their relationships, as previously reported [22,38–40].
The GeneAnalytics program produces a report containing seven categories: diseases, pathways,
tissues and cells, phenotypes, Gene Ontology (GO) molecular functions, GO biological processes,
and compounds related to the query of interest (i.e., cancer and ASD gene). Each entry in these
functional categories was sorted with the GeneAnalytics proprietary matching and scoring algorithm
following protocols published previously in the study of psychiatric, behavior, and obesity-related
genes by our research group [22,39,40]. Only those genes with the highest calculated scores were
further analyzed for each of the seven GeneAnalytics categories. In addition to scoring fields based
on their relevance to the gene set, fields were subdivided into three categories, “high-score matches”,
“medium-score matches”, and “low-score matches”. High-score matches exhibited a corrected p-value
of less than 0.05, while medium-score matches exhibited a corrected p-value between 0.05 and 0.1.
For the purposes of this investigation, medium- and low-score matches were excluded from the results.
The reporting of high-score matches was restricted to the top 30 entries, in instances where more than
30 were found to be significant (p < 0.05). Corrections were made based on multiple testing (Bonferroni
correction).
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